Back to trial details

Intake questionnaire

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Applying to Center for Neurological Disorders G · Greenfield, Wisconsin

Answer a few short questions to share with the research team.

0 of 4 answered

1. Are you between 40 and 70 years old?
2. Have you been diagnosed with Relapsing Multiple Sclerosis?
3. Are you currently pregnant or breastfeeding?
4. Are you able to travel to Greenfield for study visits?